Women who carry inactivating mutations in the BRCAI and BRCA2 genes in their germline are at of significantly elevated risk of breast and ovarian cancer. Many mutation carriers are able to take advantage of surgical prevention options that dramatically reduce the risk of developing these cancers. However, many others are found to carry Variants of Uncertain Significance (VUS), which are predominantly missense mutations. Few of these VUS have been classified as cancer predisposing or neutral variants. Thus, many carriers of these VUS mutations do not know if they are at elevated risk of cancer. As a result many women carrying VUS that may be neutral unnecessarily undergo prophylactic surgery that is associated with significant long term side effects. Here we propose to determine the cancer relevance of VUS found throughout the BRCAI and BRCA2 genes by establishing genetic and laboratory assay based methods of VUS analysis. Specifically, in Aim 1 we will classify VUS using a series of studies focusing on family history of cancer of individuals with VUS and on breast tumor pathology of individuals with VUS. To facilitate this approach we have recently established the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), a consortium aimed at classifying additional VUS through pooling of available family information from many research centers. Only through the data sharing proposed in ENIGMA will it be possible to classify a substantial number of additional mutations using genetic approaches.
In Aim 2 we will focus on establishing the sensitivity and specificity of BRCA2 functional assays for classification of BRCA2 VUS. We will not study BRCAI because many of the variants in that gene have already been characterized by functional studies. By establishing the sensitivity and specificity of the assays relative to the genetic data from Aim 1 it may be possible to classify many additional VUS with insufficient family data for direct classification by genetic methods.
In Aim 3, we will focus on developing methods for providing these results to providers and patients. This will involve evaluation of the current utilization of reclassification results, provision of results of reclassification efforts, provision of educational materials to improve this process, and evaluation of improvements in utilization of results.

Public Health Relevance

These efforts will result in determination of which carriers of VUS in BRCA1 and BRCA2 are at either high, low or even moderate risk of breast cancer. Because the study results will be provided to clinical care providers and education regrading the use of these data will be provided, the study is inherently translational. Overall, the study will ensure improved selection of VUS carriers who can benefit from various forms of intervention to prevent and/or treat breast cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Qin, Sisi; Ingle, James N; Liu, Mohan et al. (2017) Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. Breast Cancer Res 19:95
Athreya, Arjun P; Kalari, Krishna R; Cairns, Junmei et al. (2017) Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. Oncotarget 8:27199-27215
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2017) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat :
Fagerholm, Rainer; Khan, Sofia; Schmidt, Marjanka K et al. (2017) TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget 8:18381-18398
Weinshilboum, Richard M; Wang, Liewei (2017) Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc 92:1711-1722
Amos, Christopher I; Dennis, Joe; Wang, Zhaoming et al. (2017) The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 26:126-135
Engmann, Natalie J; Scott, Christopher G; Jensen, Matthew R et al. (2017) Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors. Cancer Epidemiol Biomarkers Prev 26:930-937
Vierkant, Robert A; Degnim, Amy C; Radisky, Derek C et al. (2017) Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer 17:84
Yaghjyan, Lusine; Stoll, Ethan; Ghosh, Karthik et al. (2017) Tissue-based associations of mammographic breast density with breast stem cell markers. Breast Cancer Res 19:100
Couch, Fergus J; Shimelis, Hermela; Hu, Chunling et al. (2017) Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol 3:1190-1196

Showing the most recent 10 out of 428 publications